Design Therapeutics (DSGN) Cash from Investing Activities (2020 - 2026)

Design Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$7.6 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 196.43% year-over-year to -$7.6 million; the TTM figure through Mar 2026 stood at $7.5 million (down 76.12% YoY), while the FY2025 annual figure was $22.9 million, down 47.87% from the prior year.
• Cash from Investing Activities came in at -$7.6 million for Q1 2026 at Design Therapeutics, up from -$11.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $27.3 million in Q2 2024 to a low of -$157.0 million in Q2 2022.
• A 5-year average of -$6.4 million and a median of $5.6 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities sank 1157.22% in 2022 and jumped 4666.43% in 2023, its largest moves.
• Design Therapeutics' Cash from Investing Activities stood at -$1.1 million in 2022, then soared by 626.04% to $5.6 million in 2023, then sank by 67.02% to $1.8 million in 2024, then slumped by 732.26% to -$11.6 million in 2025, then jumped by 34.48% to -$7.6 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$7.6 million, -$11.6 million, and $6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison